Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,509.06
    -1,620.40 (-3.23%)
     

  • CMC Crypto 200

    1,258.98
    -99.03 (-7.29%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

Shire eating disorder drug gets U.S. priority review

Reuters - UK Focus

LONDON, Sept 15 (Reuters) - Shire (LSE: SHP.L - news) 's hyperactivity drug Vyvanse will get a priority review in the United States as a potential treatment for binge eating disorder, showing a willingness by U.S. regulators to consider novel ways to fight eating problems.

The U.S. Food and Drug Administration last week approved Orexigen Therapeutics (NasdaqGS: OREX - news) 's long-awaited obesity pill Contrave and an advisory panel also backed Novo Nordisk (Other OTC: NONOF - news) 's injectable drug liraglutide for weight loss.

Dublin-based Shire, which is being acquired by U.S. drugmaker AbbVie (Xetra: 4AB.DE - news) , said on Monday that the FDA was expected to give its decision on the new use of Vyvanse by February 2015.

Vyvanse is currently only approved for Attention-Deficit Hyperactivity Disorder.

(Reporting by Ben Hirschler; editing by Susan Thomas)